Deep Learning With MRI-based Multimodal-data Fusion Enhanced Postoperative Risk Stratification of Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Other: MRI
- Registration Number
- NCT06546072
- Brief Summary
Breast cancer poses a significant global health challenge, especially among women, with high rates of recurrence and distant spread despite early interventions. The timely identification of metastasis risk and accurate prediction of treatment strategies are critical for improving prognosis. However, the complex heterogeneity of breast tumors presents challenges in precise prognosis prediction. Therefore, the development of innovative methods for tumor segmentation and prognosis assessment is essential.
The research conducted is a multicenter study that enrolled 1,199 non-metastatic breast cancer patients from four independent centers. Our study leverages the advancements in artificial intelligence (AI) to address this challenge. This study is the first successful application of MRI-based multimodal prediction system to precisely identify the risk of postoperative recurrence in breast cancer patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 1199
- Histologically confirmed stage I-III invasive BC
- Age ≥ 18 years
- The patient having undergone surgery
- The existence of MRI scans
- Lacked pathological results
- Had other, simultaneous malignancies
- Had MR imaging issues were excluded
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Internal validation cohort MRI We randomly assigned 569 patients from Sun Yat-sen Memorial Hospital of Sun Yat-sen University (SYSMH; Guangzhou, China) at a ratio of 3:1 to training (n = 456) and internal-validation (n = 113) cohorts. Training cohort MRI We randomly assigned 569 patients from Sun Yat-sen Memorial Hospital of Sun Yat-sen University (SYSMH; Guangzhou, China) at a ratio of 3:1 to training (n = 456) and internal-validation (n = 113) cohorts. External testing cohort 1 MRI 432 from Sun Yat-sen University Cancer Center (SYSUCC; Guangzhou, China) into external testing cohort 1. External testing cohort 2 MRI 198 from Dongguan Tungwah Hospital (DTH; Dongguan, China) and Shunde Hospital of Southern Medical University (SDHSMU; Guangzhou, China) into external testing cohort 2.
- Primary Outcome Measures
Name Time Method DFS The time from surgery to tumor recurrence, including local and/or distant recurrence, disease progression, or death, assessed up to 100 months. Disease-free survival
- Secondary Outcome Measures
Name Time Method